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 ABSTRACT 
Background: Sodium glucose co-transporter (SGLT-2) inhibitors are new class of anti-
diabetic therapy and shown to reduce cardiovascular mortality and heart failure in 
patients with T2DM with previous CV events or established cardiovascular disease.  The 
aim of the study was to determine the prescribing pattern and short-term outcomes of 
SGLT-2 inhibitors. The primary outcome was to study the effect of SGLT-2 inhibitor as 
an add-on to insulin. 
Methods: The prospective observational study was conducted which included 315 
patients receiving SGLT-2 inhibitors for the management of T2DM mellitus with eGFR 
≥40ml/min/1.73m2. The study population was divided into two- SGLT-2 + insulin ± 
OHA and SGLT-2 + OHA, which were further sub-divided based on duration of diabetes 
i.e., patients with ≤5 years and >5 years of T2DM respectively. The study was followed-
up at 2 months and 4 months. At the time of entry, complete medical history and 
laboratory evaluation were obtained. Patients demographics were also considered and 
recorded. The change in HbA1C, FBS, RBS, body weight, BMI, and lipid profile were 
measured at 2 month and 4 months. The patients were interviewed to assess ADR (if any) 
and it was confirmed by Naranjo ADR Scale. The adherence of the patients toward the 
medication was assessed with Morisky patient medication adherence scale. 
Result: The study showed that empagliflozin + biguanides + insulin + DPP-4 was the 
most prescribed combination. The glucose lowering (HbA1c, FBS and RBS) effect was 
more in empagliflozin + insulin ± OHA treated patients. Body weight, BMI and LDL was 
found decreased while HDL was slightly increased. Hypoglycemia was the mostly 
reported ADR and was more in insulin treated patients. Only one case of geno-mycotic 
infections was reported. Insulin treated patients had lower adherence towards the 
medication and hypoglycemic events was more in those patients. 
Conclusion: In conclusion, SGLT-2 inhibitor (empagliflozin) was found to significantly 
improve glycemic parameters along with reduction in body weight, BMI, and LDL with 
good effect on HDL in Indian T2DM patients with mild ADR when prescribed as add-on 
to insulin or other OHA.    
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1. INTRODUCTION 
Diabetes mellitus was first reported in Egyptian manuscript about 3000 years ago. In 
1936, the distinction between type I and type II DM was clearly made. Type II DM was first 
described as a component of metabolic syndrome in 1988.1 
Type II diabetes (formerly known as non-insulin dependent DM) is due to insufficient 
insulin production from beta cells in the setting of insulin resistance.2 Insulin resistance, which is 
the inability of cells to respond adequately to normal levels of insulin, occurs primarily within 
the muscles, liver and fat tissue. In the liver, insulin normally suppresses glucose release.3 
The prevalence of Type II DM is increasing all over the world, especially in South Asia. 
India has largest population of diabetic patients. The International Diabetes Federation (IDF) 
estimates the number of people with diabetes in India will reach 80 million by the year 2025.4 
DIABETES AND CARDIOVASCULAR DISEASE: 
 People with type II DM have two-to four-folds increased risk for coronary heart disease 
compared to those without diabetes,5 as well as other vascular disorders (consisting of heart 
failure, cardiac dysrhythmia, sudden death, hypertensive disease, pulmonary embolism, and 
aortic aneurysm). Heart failure is a particularly common complication of T2DM and is 
associated with poor outcomes.6 The risk associated with diabetes is higher at younger ages and 
lower at higher ages. For instance, at the age of 60 years, a patient with T2DM and 
cardiovascular disease (CVD) has reduced life expectancy of 12 years compared with the general 
population, according to a study by the Emerging Risk Factors Collaboration (689,300 
participants; 91 European cohorts), 7 and of 2 years at age 67 years in Sweden.5 There is, 
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therefore, a need for novel treatment for T2DM that not only improve glycemic control but also 
reduce the risk of CVD. 
MANAGEMENT OF TYPE II DIABETES MELLITUS – “CARDIOVASCULAR 
CONSIDERATION”: 
 Historically, the aim of glucose-lowering therapy in diabetes is to reduce microvascular 
complications. Whereas, interventional studies focused on intensive glucose reduction in T2DM 
have only had a minor or no effect in reducing cardiovascular risk.8 In 1998, the UK Prospective 
Diabetes Study (UKPDS) found that a subgroup of obese patients randomized to metformin had 
a reduction in myocardial infraction.9Since then, metformin had become the standard first-line 
drug treatment for T2DM.10 In the last two decades, numerous therapeutic options have emerged 
for T2DM, including dipeptidyl peptidase-4 inhibitor (DPP-4i), glucagon-like peptide-1 (GLP-1) 
receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. 
 In 2008, following the withdrawal of rosiglitazone from the market because of its 
association with increased risk of HF and MI,11 the US Food and Drug Administration (FDA) 
mandated CV outcome trials (CVOTs) on glucose-lowering drugs (GLDs).12 In 2012, the 
European Medicines Agency (EMA) also published a guideline requiring CVOTs for new GLDs 
for which specific CV claims are made or that are suspected of having detrimental CV effects.13 
As a result, two drugs – empagliflozin (an SGLT-2 inhibitor) and liraglutide (a GLP-1 receptor 
agonist) – have a level A recommendation in the American Diabetes Association (ADA) 2018 
Standards of Medical Care in Diabetes.14 
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Class Generic names 
Mechanism of 
action 
CV outcomes 
Sulfonylureas GliclazideGlimepirideGlyburide
Stimulate 
pancreatic insulin 
secretion 
Possible increase 
in CV death 
Biguanides Metformin 
Inhibit hepatic 
glucose 
production 
Possible CV 
benefits supported 
by small trials and 
number of events 
Thiazolidinediones 
Pioglitazone 
Rosiglitazone 
Increase insulin 
sensitivity and 
reduce hepatic 
glucose 
production 
Pioglitazone CV 
benefits. 
Rosiglitazone 
increases risk of 
HF 
DPP-4 inhibitors 
Linagliptin 
Saxagliptin 
Sitagliptin 
Alogliptin 
Intensify the 
effect of the 
intestinal 
incretins 
Saxagliptin and 
alogliptin increases 
the risk for HF 
whereas sitagliptin 
has no CV effect 
GLP-1 agonists 
Exenatide 
Liraglutide 
Mimics the effect 
of incretins 
Reduce CV death 
SGLT-2 receptor 
inhibitors 
Empagliflozin 
Canagliflozin 
Dapagliflozin 
Inhibit renal 
glucose 
reabsorption 
favouring renal 
excretion 
Decrease CV death 
and HF 
hospitalization, 
rare 
hypoglycaemia, 
decrease blood 
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Table 1: Class, generic name, mechanism of action, and side effect on CV outcomes of 
most commonly used hypoglycemic drugs.15 
 
SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT-2) INHIBITORS: 
 Inhibitors of sodium-glucose cotransporters type-2 (SGLT-2) are new glucose-lowering 
agents with an original insulin-independent mode of action developed for the treatment of type-II 
diabetes mellitus.16 They specifically target the kidney by blocking the reabsorption of filtered 
glucose. This effect results in increased urinary glucose excretion, especially when 
hyperglycemia is present and provided that renal function is maintained.17 This mechanism of 
action holds promise for patients with T2DM not only in terms of improvements in glycemic 
control, with a limited risk of hypoglycemia, but also considering the potential benefits of weight 
loss resulting from increased glucosuria and arterial blood pressure reduction associated with the 
osmotic/diuretic effect.18 These agents share a negligible risk of drug–drug interactions, an 
interesting characteristic in T2DM patients generally exposed to multiple pharmacological 
agents.19 However, caution is requested in patients with renal impairment.20 Numerous 
randomized controlled trials (RCTs) evaluated SGLT2 inhibitors as monotherapy in diet-treated 
patients or as add-on therapy to different glucose-lowering agents, including insulin.21,22  They 
are now integrated as second or third-line therapy in the algorithm of the 2015 position statement 
by the American Diabetes Association (ADA) and the European Association for the study of 
Diabetes (EASD).23  
FDA APROVED SGLT-2 INHIBITORS: 
pressure and body 
weight 
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1. Empagliflozin (Boehringer Ingelheim and Eli Lilly, approved as Jardiance by US 
FDA in 2014).24 
2. Dapagliflozin (AstraZeneca, approved as Farxiga by US FDA in 2014).25 
3. Canagliflozin (Janssen Pharmaceuticals, approved as Invokana by US FDA in 
2013).26 
PHYSIOLOGY OF RENAL GLUCOSE REABSORBTION: 
At normal concentrations of plasma glucose, the kidneys actively reabsorb almost all 
filtered glucose (approximately 180 g/day) with less than 1% excreted in the urine.Glycosuria 
occurs when plasma glucose concentrations exceed the glucose reabsorbing capacity of the 
proximal tubules. This renal threshold for glucose is about 11 mmol/L.27 
Glucose is a hydrophilic molecule which needs to be transported across cell membranes 
to enter cells. Glucose transport can either be facilitative or active. Facilitative transport is driven 
by the concentration gradient across the cell membrane. Active transport is driven by sodium co-
transport. Uptake of glucose in the intestine and kidneys is by active transport, mediated by 
members of the SGLT family. SGLT-1 and SGLT-2 are responsible for glucose reabsorption in 
the proximal tubules of the kidneys (Fig. 1).28 
SGLT-2 is a low-affinity, high capacity glucose transporter located in segment 1 of the 
proximal tubule (in the apical membrane of the tubule cells). Under normal circumstances 
SGLT-2 reabsorbs about 90% of the filtered glucose (Fig. 2). SGLT-2 is minimally expressed in 
other tissues.29 
SGLT-1 is a high-affinity, low capacity glucose transporter predominantly found in 
enterocytes of the small intestine where it transports glucose and galactose from the gut lumen 
across the gut wall. In the kidney SGLT-1 is located in segments 2–3 of the proximal tubule. 
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Figure 2: Action of SGLT2 in the proximal tubule.30 
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PHARMACOLOGY OF SGLT-2 INHIBITORS: 
TheSGLT-2 inhibitors approved by FDAare empagliflozin, dapagliflozin and 
canagliflozin, have high bioavailability. These drugs can be taken once a day, preferably before 
the first meal of the day. These drugs are highly protein bound in plasma and are metabolized in 
the liver via glucuronidation.With these characteristics there is a low propensity for 
pharmacokinetic drug–drug interactions. However, inducers of glucuronidation can cause a 
modest increase in the metabolism of SGLT-2 inhibitors. When inducers of glucuronidation (e.g. 
rifampicin, phenytoin or ritonavir) are prescribed, the product information for canagliflozin 
recommends a higher dose of 300 mg daily (usual starting dose 100 mg daily) or using an 
alternative blood glucose-lowering drug. The product information for dapagliflozin and 
empagliflozin does not recommend a dose increase. Inhibition of metabolism by other 
glucuronidated drugs, for example mefenamic acid, is possible.31The clinical significance of 
these potential interactions with either drug is likely to be low. Canagliflozin may increase the 
plasma concentration of digoxin so digoxin concentrations should be monitored when starting or 
stopping canagliflozin. 
Pharmacodynamic drug interactions may occur with thiazides and loop diuretics, 
increasing diuresis and the risk of dehydration. Changes in renal tubular handling of potassium 
associated with SGLT-2 inhibition may be significant in patients at higher risk of hyperkalaemia, 
for example those with baseline renal impairment, taking ACE inhibitors or taking potassium-
sparing diuretics.30 
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In patients with mild to moderate liver impairment, no significant increase in drug 
concentrations was seen with either drug. A lower starting dose of dapagliflozin (5 mg) is 
recommended in patients with severe liver disease. There are no published data for canagliflozin 
and empagliflozin in severe liver disease. 
According to EMPA-REG32 and CANVAS33 trials, the reported adverse events 
associated with empagliflozin and canagliflozin are genital mycotic infections and diabetic 
ketoacidosis. 
Bladder cancer was reported with canagliflozin which diminish the clinician favor. 
EMPAGLIFLOZIN: 
 Empagliflozin is the latest SGLT-2i approved by US FDA for the treatment of T2DM. In 
the EMPA-REG OUTCOME32 trial, empagliflozin added to standard of care reduced the risk of 
3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-
fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for 
heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) 
and established CV disease. 
• Empagliflozinis chemically (1S)-1,5-anhydro-1-(4 – chloro-3-{4-[(3S)-
tetrahydrofuran-3-yloxy] benzyl} phenyl)-D-glucitol. 
Figure 3: Chemical structure of Empagliflozin34 
 
 
 
 
• Empagliflozin is available in 10 mg and 25 mg, should be taken once a day. 
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• It had the elimination half-life of about 12.4 hour. 
• After oral administration, empagliflozin was rapidly absorbed with peak plasma 
concentrations (Cmax) with a median time to reach Cmax (tmax) of 1.5 h post-dose. 
• The apparent steady-state volume of distribution was estimated to be 73.8 L 
plasma protein binding was 86.2%. 
• primary route of metabolism of empagliflozin in humans is glucuronidation by the 
uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, 
and UGT1A9. 
• The apparent oral clearance was 10.6 L/h based on the population 
pharmacokinetic analysis. 
• Approximately 54.4% of the drug are excreted through urine. 
CANAGLIFLOZIN: 
 CANVAS33 trial proofs the effect of treatment with canagliflozin on cardiovascular, 
renal, and safety outcomes. In two trials involving patients with T2DM and an elevated risk of 
cardiovascular disease, patients treated with canagliflozin had lower risk of cardiovascular events 
than those who received placebo but greater risk of amputation, primarily at the level of the toe 
or metatarsal. 
• Canagliflozin is available in 100 mg and 300 mg tablets, should be taken once a 
day. 
• Canagliflozin is chemically (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-
2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol. 
• Canagliflozin is rapidly absorbed achieving peak plasma concentration in 1-2 
hours and has a bioavailability of 65%. 
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• It is glucuronidated into two inactive metabolites, M7 and M5 by uridine 
diphosphate-glucuronosyltransferase (UGT) 1A9 and UGT2B4, respectively. 
Figure 4: Chemical structure of Canagliflozin35 
 
• Reaches steady state in 4 days. 
• The half-life of orally administered canagliflozin 100 mg and 300 mg in healthy 
participants is 10.6 and 13.1 hours, respectively. 
DAPAGLIFLIOZIN: 
 DECLARE-TIMI5836 trial demonstrate the effect of dapagliflozin on cardiovascular 
outcomes when added to standard therapy in patients with T2DM with either established 
cardiovascular disease or cardiovascular risk factors. 
Figure 5: Chemical structure of Dapagliflozin37 
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• Dapagliflozin achieve peak plasma concentration within 2 hours. 
• Bioavailability 78% 
• Dapagliflozin metabolism occurs predominantly in the liver and kidneys by 
uridine diphosphate-glucuronosyltransferase-1A9 to the major metabolite 
dapagliflozin 3-O-glucuronide. 
• The half-life for orally administered dapagliflozin 10 mg is 12.9 hours. 
• Maximal increases in urinary glucose excretion were seen at doses ≥20 mg/day 
in patients with T2DM. 
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CARDIO-RENAL BENEFITS AND RISK ASSOCIATED WITH SGLT-2 INHIBITORS – 
“PROPOSED MECHANISM”: 
Figure 6: Integrated physiological basis for proposed mechanisms leading to cardiorenal 
benefits and risks associated with sodium glucose cotransport-2 inhibition.38 
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MAJOR CLINICAL TRIALS WITH SGLT-2 INHIBITORS: 
Table 2: List of major clinical trials conducted for SGLT-2 inhibitor.38 
Name of Clinical 
Trial 
Type 
Treatment 
Arms 
Duration Sample Size 
CARDIOVASCULAR OUTCOME TRIALS 
EMPA-
REGOUTCOME 
(Empagliflozin 
Cardiovascular 
Outcome Event Trial 
in Type 2 Diabetes 
Mellitus 
Patients) 
Double-blind, 
placebocontrolled
RCT (phase 3) 
Empagliflozin10 
mg or 25mg 
daily vs placebo 
Up to4.6 
years 
7020 patients 
with established 
cardiovascular 
complications 
(≥18 y) 
CANVAS Program 
(Canagliflozin 
Cardiovascular 
AssessmentStudy) 
Double-blind, 
placebocontrolled
RCT (phase 3) 
Canagliflozin 
100 mg or 
300 mg daily vs 
placebo 
3.6 years 
10 142 patients 
with 
established 
vascular 
complications or 
≥2 
cardiovascular 
risk 
factors 
(>30 y) 
CREDENCE 
(Evaluation of the 
Effects of 
Canagliflozin 
on Renal and 
Cardiovascular 
Outcomes in 
Double-blind, 
placebocontrolled
RCT 
(phase 3) 
Canagliflozin 
100 mg daily 
vs placebo 
4 years 
3627 patientswith 
stage 2 or 3 
CKDand 
macro-
albuminuriaand 
on ACEi/ARB 
(>30 y) 
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Participants with 
Diabetic 
Nephropathy) 
DECLARE-TIMI 58 
(Multi-centre Trial to 
Evaluate 
the Effect of 
Dapagliflozin on the 
Incidence of 
Cardiovascular 
Events) 
Double-blind, 
placebocontrolled
RCT (phase 3) 
Dapagliflozin 
10 mg vs 
placebo 
Up to 6 
years 
17,276 patients 
with high risk for 
cardiovascular 
events 
(≥40 y) 
EMPEROR-
Preserved 
(Empagliflozin 
Outcome Trial in 
Patients with 
Chronic Heart 
Failure with 
Preserved 
Ejection Fraction) 
Double-blind, 
placebocontrolled
RCT 
(phase 3) 
Empagliflozin 
10 mg daily 
vs placebo 
38 
months 
4126 patients with 
HFpEF (≥18 y) 
SGLT-2 INHIBITORS IN TYPE II DIABETES MELLITUS: 
 Treatment with an SGLT-2 inhibitor causes dose-dependent urinary net glucose loss of 
20–70g per day. This varies with the degree of hyperglycemia. The US Food and Drug 
Administration analyses of clinical trials found dapagliflozin reduces glycated hemoglobin 
(HbA1C) in patients with type 2 diabetes by 4–9 mmol/mol (0.4–0.8%), depending on the initial 
HbA1C32.Similarly, for canagliflozin there was a dose-dependent HbA1C reduction of 4–11 
mmol/mol (0.4–1%),31whereas empagliflozin shows 0.6-1% reduction in HbA1C.36This is 
comparable to the effect of dipeptidyl peptidase 4 inhibitors, but less than that of metformin, 
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sulfonylureas or glucagon-like peptide-1 analogue.39The reduction in blood glucose 
concentrations occurs independently of any increase in insulin concentrations or decrease in 
peripheral insulin resistance. In addition, the glycosuria causes a caloric loss, which has been 
associated with an average weight loss of 2–3 kg over 6–12 months in clinical trials. 
 According to American Diabetes Association, 2017 guidelines40 for the treatment of type 
II diabetes mellitus, SGLT-2 inhibitors shall be used as dual-therapy or triple-therapy with other 
oral hypoglycemic drugs (OHD). 
POSITION OF SGLT-2 INHIBITORS IN AMERICAN DIABETES ASSOCIATION 
GUIDELINES: 
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Figure 7: Pharmacologic therapy for type II diabetes by ADA,201740 
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According to American Diabetes Association (ADA), American Association of Clinical 
endocrinologists (AACE), European Society and NICE (UK) guidelines suggest that SGLT-2 
inhibitors should be considered over other oral hypoglycemic therapy especially in patients 
having established cardiac disease or risk of cardiovascular disease with/or increased incidence 
of hypoglycemia and/or weight gain. The present study plays an important role in focusing the 
effect of SGLT-2 inhibitor as an add-on to insulin or other OHA.  
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2. LITERATURE REVIEW 
 Laffelet al., (2018)41 conducted a single dose, open-label, randomized, parallel 
group study with empagliflozin 5 mg, 10 mg and 25 mg in 39 young people 
with T2DM aged 10-17 years to assess the pharmacokinetic and 
pharmacodynamic profile of single dose empagliflozin. The study shows there 
is a dose-dependent increase in urinary glucose excretion, along with decrease 
in plasma blood glucose and body weight. 
 Joboriet al., (2018)42 included 15 patients with T2DM for an open-label study 
in which all the patients were treated with 25 mg empagliflozin/day and 
received a hyperglycaemic clamp before and at 48 hours and 14 days. The 
study shows, lowering the plasma glucose concentration with empagliflozin 
cause a rapid increase in β-cell function. The effect of empagliflozin occurs 
rapidly and last for the entire treatment period (i.e., 14 days). 
 Inzucchiet al., (2018)43conducted an exploratory analysis to identify the 
mechanism behind 38% reduction in the risk of CV death observed with 
empagliflozin versus placebo in patients with T2DM and established CVD in 
EMPA-REG OUTCOME trial which included 7020 patients.The primary 
analysis of CVD with empagliflozin versus placebo was based on Cox 
proportional hazard regression model. The study shows, changes in the 
haematocrit and haemoglobin which play a role in plasma volume appears to 
be the variables with largest impact on HR and CV death with empagliflozin 
and placebo group.  
 Xiaolinget al., (2018)44conducted a meta-analysis with 55 placebo control trial 
to evaluate the weight changes associated with different SGLT-2 inhibitors. 
The study summaries that there was significant reduction in the body weight 
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(empagliflozin 10 mg and 25 mg shows -1.84 kg and -1.93 kg respectively) in 
patients with T2DM who received different doses of SGLT-2 inhibitors. 
 Verma et al., (2018)45 conducted a sub-analysis of EMPA-REG OUTCOME 
trial, in which they randomized patients with self-reported history of coronary 
artery bypass graft (CABG) in empagliflozin 10 mg, 25 mg and placebo group. 
The study concludes, there was a profound reduction in the cardiovascular and 
all-cause mortality, hospitalization for heart failure, and incidences of 
worsening nephropathy. These data have important implications for secondary 
prevention of cardiovascular events after CABG in individuals with T2DM. 
 Zinmanet al., (2018)32 performed a sub-analysis of EMPA-REG OUTCOME 
trial to determine the relative CV prevention effect of empagliflozin in women 
versus men in which they compared 2004 women and 5016 men. In 
conclusion, CV death, HF hospitalization, and incident or worsening 
nephropathy rate reduction induced by empagliflozin were not different 
between men and women. 
 Iraceet al., (2018)46 designed a non-randomized, open, prospective cohort 
study including 35 T2DM outpatients who received empagliflozin in 
combination with insulin or metformin to study the effect of empagliflozin on 
blood viscosity and shear stress in carotid arteries. Blood viscosity, shear stress 
and carotid wall thickness were measured at 1 and 3 months. This study is the 
first reported the empagliflozin caused increase in haematocrit, blood viscosity 
and wall shear stress. IMT was markedly reduced. 
 Refardtet al., (2018)47 performed a double-blind placebo-controlled 
randomised crossover study in 14 healthy volunteers to study the short-term 
urinary volume output in syndrome of inappropriate antidiuresis (SIADH). 
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They induced an artificial SIADH model by administration of desmopressin 
and overhydration. Afterwards, 25 mg empagliflozin or placebo was given. In 
SIADH model, empagliflozin increased urinary excretion due to osmotic 
diuresis and due to short-term treatment, serum sodium level remained 
unchanged. Further, real-life study needed to examine empagliflozin as a new 
treatment for SIADH. 
 Yasuiet al., (2018)48 randomized 100 Japanese T2DM patients to receive 1, 5, 
10 and 25 mg empagliflozin or placebo once daily. Changes from baseline 24-
hour urine volume and fluid intake were assessed at 1, 27 and 28 days after the 
initiation of empagliflozin. Finally, treatment initiation with empagliflozin was 
associated with transient diuresis; overall urine volume return towards baseline 
level within 4 weeks of treatment. 
 Kohler et al., (2018)49 assessed the effect of empagliflozin on bone fractures 
and bone mineral density in patients with T2DM in pooled placebo-controlled 
trial and head-to-head study versus glimepiride. In the trials, they randomized 
the patients to receive 10 mg or 25 mg empagliflozin and placebo. The study 
shows, empagliflozin did not increase the risk of bone fracture compared with 
placebo in pooled analysis of >12000 patients or compared with glimepiride in 
4-year head-to-head study. 
 Hattori et al., (2018)50 conducted an open label, single centre, prospective 
study which included 109 T2DM patients. Empagliflozin 10 mg or placebo 
was randomly administered once daily for 12 weeks as add-on therapy. The 
empagliflozin treated group shows, significant reduction in the blood glucose 
along with remnant-particle cholesterol (RLP-C) which is closely associated 
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with amelioration of insulin sensitivity in diabetic patients who have insulin 
resistance. 
 Kuchayet al., (2018)51 randomly assigned 50 T2DM patients into either 
empagliflozin group (10 mg empagliflozin + standard treatment for T2DM) or 
control group (standard treatment for T2DM without empagliflozin) for 20 
weeks. Change in liver fat was measured by MRI-derived proton density fat 
fraction (MRI-PDFF). As a result, empagliflozin shows a reduction in the liver 
fat and improves ALT level in patients with T2DM and non-alcoholic fatty 
liver disease (NAFLD). 
 Muller et al., (2018)52 conducted a double-blind, randomized, placebo-
controlled study to examine the effect of empagliflozin 10 mg in renal tissue 
oxygenation in non-diabetic patients, which can be measured by blood 
oxygenation level-dependent magnetic resonance imaging (BOLD-MRI). They 
grouped into normal, over-weight and obese non-diabetic patients, each 
contain 15 subjects. BOLD-MRI was measured before and 180 min after the 
administration of empagliflozin 10 mg or placebo. The sequence of 
measurement was repeated after 1 month of empagliflozin or placebo 
treatment. Finally, they concluded that empagliflozin has a profound effect on 
renal physiology and inhibition of SGLT-2 with empagliflozin affects the renal 
tissue oxygenation, determined by BOLD-MRI. This is the first study that 
reflects inhibition of SGLT-2 with empagliflozin. 
 Nunez et al., (2018)53 conducted a pilot study with 19 T2DM patients who has 
previous history of heart failure and they underwent cardiopulmonary exercise 
testing before and 30 days after initiation of empagliflozin therapy. In this 
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study, empagliflozin was associated with 1-month exercise improvement 
capacity in T2DM patients with symptomatic HF. 
 Kawamoriet al., (2018)54 conducted a trial by including 433 patients who 
were previously receiving anti-diabetic drugs for ≥12 weeks. Patients who 
were previously treated with linagliptin were then randomized to treated with 
empagliflozin or placebo. The HbA1C level was recorded at 12, 28 and 54 
weeks. The study concludes, empagliflozin-linagliptin combination therapy is a 
good glucose lowering therapeutic option for Japanese T2DM patients. 
 Shiba et al., (2017)55randomized 1403 T2DM patients to receive empagliflozin 
10 mg, 25 mg and placebo. Empagliflozin was well tolerated and the HbA1C, 
fasting plasma glucose and body weight was improved across age and degree 
of obesity. 
 Tanaka et al., (2017)56 performing an ongoing trial to study the effect of 
empagliflozin on endothelial function (EMBLEM trial). They randomized 110 
T2DM patients with known history of CVD to receive empagliflozin 10 mg 
once daily or placebo. The primacy outcome of the trial is change in reactive 
hyperemia(RH)-peripheral arterial tonometry-derived RH index at 24 weeks 
from baseline. The secondary outcomes include, change from baseline for 
vascular related markers like arterial stiffness, sympathetic nervous activity, 
and parameters for cardiac and renal functions. EMBLEM is the first trial to 
assess the effect of empagliflozin on endothelial function in patients with 
T2DM and established CVD. 
 Kaku et al., (2017)57 randomised 1517 Asian race T2DM patients to receive 
empagliflozin 10 mg, 25 mg or placebo which is 21.6% of EMPA-REG trial 
population. The study shows reduction in the CV risk and all-cause mortality 
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with empagliflozin vs. placebo were consistent between Asian population and 
overall population in EMPA-REG trial. 
 Mordiet al., (2017)58 prepared a protocol for RECEBE-CHF which is a 
randomized controlled, double blind, cross-over trail, where they include 34 
patients with T2DM and known CHF. Renal physiology test was performed at 
two points: 1 and 6 weeks for each group (empagliflozin 25 mg and placebo). 
The participants were enrolled in the trial for 16 weeks. The primary outcome 
was to study the effect of empagliflozin vs placebo on urine output. The 
secondary outcome was to study the effect of empagliflozin on glomerular 
filtration rate, cystatin C, urine sodium excretion, urine protein/creatinine ratio 
and urine albumin/creatinine ratio when compared with placebo. 
 Zinmanet al., (2017)59 randomized 7020 patients to receive empagliflozin 10 
mg, 25 mg or placebo with mean observation time for 3.1 years. They 
concluded that patients who received empagliflozin versus placebo doesn’t 
show either reduction or increase in the risk of cerebrovascular events. 
 Cherneyet al., (2017)60 randomly assigned 7028 patients aged 18 years and 
above with T2DM and established CVD to receive empagliflozin 10 mg, 25 
mg or placebo until 691patients experienced an arbitrated event included in the 
primary outcomes. They analysed the urine albumin-to-creatinine ratio 
(UACR) and concluded that empagliflozin shows significant reduction in the 
UACR from early as week 12 and was maintained under chronic treatment. In 
the study the effect of empagliflozin on microalbuminuria and 
macroalbuminuria seems to be at least equivalent to RAS inhibitors. 
 Wanneret al., (2016)61 randomly included 7020 patients with T2DM and an 
estimated GFR of at least 30ml per minute to receive empagliflozin (10mg or 
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25mg) or placebo once daily. About 12.7% of the patients in empagliflozin 
group and 18.8% in placebo group reported worsening or incidence of 
nephropathy. They concluded that empagliflozin was related to slower 
progression of kidney disease and lower rate of clinically relevant renal events. 
 Softelandet al., (2016)62 conducted a 24-week double blind randomized study 
where they included patients with previous therapy by linagliptin for 16 weeks. 
The patients are then randomized to receive empagliflozin 10mg, 25mg or 
placebo for 24 weeks. They concluded that, empagliflozin was associated with 
improved glycaemic control and weight versus placebo as an add-on treatment 
to linagliptin 5mg. 
 Thomas et al., (2016)63 conducted a retrospective study to assess adoption rate 
of anti-obesity pharmacotherapies and SGLT-2i. They extracted the 
prescribing pattern data from Prescription AuditTM and XponentTM. The study 
concluded that, the number of prescriptions for antidiabetics was 15 times the 
number for anti-obesity and mean increase in prescription/month were 25,259 
for SGLT-2, 5154 for new anti-obesity therapy. 
 Neelandet al., (2015)64randomized 3300 patients with T2DM to receive 
empagliflozin 10mg, 25mg or placebo in clinical trial of 12 weeks duration. 
They assessed the change in body weight, waist circumference, estimated total 
body fat, index of central obesity and visceral adiposity index. The study 
concludes a significant reduction in the body weight and adipose indices along 
with improvement in the cardiometabolic risk among patients with T2DM in 
the empagliflozin group. 
 Nishimuraet al., (2015)65randomized 60 T2DM patients to receive 
empagliflozin 10mg, 25mg or placebo once daily as monotherapy for 28 days. 
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The effect of empagliflozin on PPG and 24-hour glycaemic variability in 
Japanese patients with T2DM were studied. The study shows, empagliflozin 
was associated with reduction in the PPG from first day and improved daily 
glucose control in Japanese patients with T2DM. 
 Defronzoet al., (2015)66 randomized 686 patients to receive empagliflozin 
25mg/linagliptin or empagliflozin 10mg/linagliptin or empagliflozin 25mg or 
empagliflozin 10mg as add-on to metformin for 52 weeks. The primary 
endpoint was change from baseline HbA1c at week 24. The conclusion was, 
empagliflozin/linagliptin as second-line therapy shows a significant reduction 
in the HbA1c compare to individual components in 52 weeks study. 
 Kovacs et al., (2015)67investigated the safety and efficacy of empagliflozin as 
an add-on to pioglitazone with or without metformin, for which they 
randomized 498 T2DM patients to receive empagliflozin 10mg, 25mg or 
placebo for 24 weeks in EMPA-REG PIOTM study. They assessed the change 
in glycaemic control, body weight, as primary consideration and concluded 
that empagliflozin 10mg or 25mg as add-on therapy to pioglitazone with or 
without metformin was well tolerated and HbA1c and body shows a significant 
reduction. 
 Pieberet al., (2015)68 randomized 75 T1DM patients with HbA1c ≥7.5 to 
≤10.5% to receive empagliflozin 2.5mg, 10mg, 25mg or placebo as adjunct to 
insulin for 28 days. The primary outcome was change in baseline in 24-hour 
urinary glucose excretion on day 7. In patients with type 1 diabetes, 
empagliflozin for 28 days as adjunct to insulin increased UGE, improved 
HbA1c and reduced weight with lower insulin doses compared with placebo 
and without increasing hypoglycaemia. 
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 Zinmanet al., (2015)69 randomized 7020 T2DM patients with established 
cardiovascular disease to receive empagliflozin 10mg, 25mg or placebo once 
daily. The primary composite outcome was death from cardiovascular causes, 
nonfatal stroke or nonfatal myocardial infraction with the mean observation 
time of 3.1 years. The study shows 38% reduction in the death due to CV 
causes, 37% reduction in the hospitalization due to HF and 32% reduction in 
the death from any cause in the empagliflozin group as compared to placebo. 
 Rosenstock et al., (2015)70 randomized 500 inadequately controlled T2DM 
patients to receive empagliflozin 10mg, 25mg or placebo for 78 weeks. The 
primary outcome was change in baseline HbA1c at 18 weeks and secondary 
outcome were change in HbA1c and insulin dose at week 78. They concluded 
that empagliflozin added to basal insulin improved glycaemic control and 
reduced weight with similar risk of hypoglycaemia to placebo. 
 Kadowakiet al., (2015)71 conducted a randomized, double blind, placebo 
controlled, dose finding, 52-week, phase IIb trial in Japanese T2DM patients. 
They randomized the patients to receive empagliflozin 5mg, 10mg, 25mg, 
50mg or placebo for 12 weeks followed by extension of 40 weeks for 
empagliflozin 10mg and 25mg. The study shows, empagliflozin 10mg and 
25mg as monotherapy results in the significant reduction in HbA1c, FPG, body 
weight and blood pressure. 
 Araki et al.,(2015)72conducted a study in T2DM patients who were previously 
received with biguanides, thiazolidinedione, α-glucosidase inhibitor, or DPP4 
inhibitor to received empagliflozin 10 or 25mg as add-on for 52 weeks. The 
change from baseline glucose level at 52 weeks was the endpoint and they 
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concluded that empagliflozin as add-on to other oral anti-diabetic therapy for 
52 weeks were well tolerated and were associated with reduction in HbA1C.   
 Haeringet al., (2015)73 randomized T2DM patients who where inadequately 
controlled on metformin or sulfonylurea were randomized to receive 
empagliflozin 10mg or 25mg or placebo. The primary end point was change 
from baseline HbA1C and secondary outcome was change in body weight and 
mean daily glucose at 24 hours. The study shows, empagliflozin as an add-on 
to metformin or sulfonylurea were associated with reduction in HbA1C, body 
weight and mean glucose. 
 Halimiet al., (2014)74 studied the safety and adverse effects of SGLT-2 
inhibitors. The study reports the events of genital mycotic infections and 
urinary tract infections in female patients, but rarely. The study shows, the 
beneficial effects on body weight, glucose control, blood pressure and 
triglycerides. Reported events of hypoglycaemia was lower. 
 Ridderstraleet al., (2014)75 conducted a double-blind phase-III trail in which 
they randomized T2DM patients to receive empagliflozin 25mg once daily or 
glimepiride 1-4mg once daily as add-on to metformin for 104 weeks. The 
primary composite outcomes were change in baseline HbA1c level at 52 and 
104 weeks. The study shows, empagliflozin is not inferior to glimepiride and 
well tolerated and effective as second-line treatment for patients with T2DM 
who have not achieved good glycaemic control on metformin. 
 Kadowakiet al., (2014)76 randomized 547 T2DM Japanese patients to receive 
empagliflozin 5mg, 10mg, 25mg, 50mg or placebo for 12 weeks. The 
glycaemic control test was done at 12 weeks. The reported adverse events were 
lesser in empagliflozin group as compared to placebo. The conclusion was, 
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empagliflozin as monotherapy reduced HbA1c, FPG, body weight, and SBP 
and was well tolerated. 
 Rosenstock et al., (2014)77 randomized T2DM patients who were inadequately 
comtrolled on insulin + metformin to receive empagliflozin 10 or 25mg or 
placebo once daily as an add-on to insulin for 52 weeks. The primary endpoint 
was change from baseline HbA1C at week 18. The secondary outcome was 
change in insulin dose, HbA1C and body weight at week 52. The study shows a 
reduction in the HbA1C, body weight and insulin dose after 52 weeks. 
 Rodenet al., (2013)78 conducted a randomized, double-blind, placebo 
controlled, phase-III trial. They randomized the patients with previous history 
of receiving anti-diabetic treatment for 12 weeks to receive empagliflozin 
10mg, 25mg, placebo or sitagliptin 100mg once daily for 24 weeks. The 
change in HbA1c from baseline were recorded. The study show, empagliflozin 
shows a tolerable and efficacious strategy to reduce HbA1c in patients with 
T2DM who had previously received anti-diabetic treatment.  
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3. AIM AND OBJECTIVES 
AIM 
 To study the prescribing pattern and short-term outcomes of SGLT-2 inhibitors 
in patients with Type II Diabetes mellitus aged 20 years and above in a tertiary care 
hospital. 
OBJECTIVES 
 To study the glucose lowering effect of SGLT-2 inhibitors with insulin or 
OHA in ≤5 years and >5 years of Type II Diabetes mellitus. 
 To study the change in body weight and lipid profile in patients receiving 
SGLT-2 inhibitors. 
 To study the ADR associated with add-on therapy of SGLT-2 inhibitors along 
with patient medication adherence. 
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4. METHODOLOGY 
STUDY SITE: 
 The study was performed in the Department of Diabetology and 
Endocrinology, Kovai Medical Center and Hospital (KMCH) at Coimbatore, 
Tamilnadu, India. The proposed protocol for the study was presented and approved by 
the Hospital Ethical Committee (Annexure 1). 
STUDY DURATION: 
 The study was carried out from 10th February 2018 to 25th August 2018 (6 
months). 
STUDY POPULATION: 
 The study is a hospital based prospective study in which all the patients 
receiving SGLT-2 inhibitor for the management of T2DM from the Diabetology and 
Endocrinology department, Cardiology department and General medicine department 
were considered. The study included describing data collected in terms of their level 
of measurement and summarizing them in form of tables, graphs and numerical 
values. Mainly the Paired ‘t’ test was used to finalize the study. 
SOURCE DATA: 
 Patient medical record – Patient medical record is observed and the required 
data such as register no., age, gender, comorbidities, body weight, BMI, FBS, RBS, 
HbA1C, total cholesterol, triglycerides, HDL, LDL, eGFR, and received therapy was 
recorded. The social habits, duration of comorbidities, ADR and the patient 
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medication adherence were noted by using Morisky Patient Medication Adherence 
Scale was done by direct interviewing the patient. 
STUDY CRITERIA: 
 Inclusion criteria: Any T2DM patient aged 20 years and above receiving 
SGLT-2 inhibitor with eGFR ≥40ml/min/1.73m2. 
 Exclusion criteria: Patient aged less than 20 years, pregnant woman, T1DM 
and eGFR ≤40ml/min/1.73m2 were excluded from the study. 
METHOD OF DATA COLLECTION: 
 Data collection form. 
 Naranjo Adverse Drug Reaction Scale. 
 Morisky Patient Medication Adherence Scale. 
 Communication with the patients. 
STUDY PROTOCOL: 
 The study was carried out after receiving approval from the Ethical committee 
of the hospital on 10th February, 2018. The patients receiving SGLT-2 inhibitor for the 
management of T2DM with eGFR ≥40ml/min/1.73m2 were included in the study .A 
total of 315 patients were studied by the time period of 6 months. The essential data 
such as, patient’s demographics information’s, past medical history and clinical data 
such as, body weight, BMI, FBS, RBS, HbA1C, total cholesterol, triglycerides, HDL, 
LDL, eGFR rate, prescribed drugs were collected using data collection form. The 
reported ADR was confirmed by Naranjo ADR Scale and adherence questionnaire 
was used to note the patient’s medication adherence. All the data were assessed based 
on duration of T2DM mellitus.   
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5. TABLES AND GRAPHS 
 
Table 3: Distribution of study population based on gender (n=315) 
GENDER POPULATION PERCENTAGE (%) 
MALE 188 59.68 
FEMALE 127 40.31 
 
 
Figure 9: Plot for overall study population based on gender (n=315) 
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Table 6: Distribution of study population based on BMI (n=315) 
CATEGORY POPULATION PERCENTAGE (%) 
Underweight 0 0 
Normal 14 4.44 
Over-weight 200 63.49 
Obese 102 32.06 
 
 
Figure 12: Plot of overall study population based on BMI(n=315) 
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Table 7: Distribution of study population based on duration of T2DM (n=315) 
DURATION POPULATION PERCENTAGE (%) 
1-5 Years 54 17.14 
6-10 Years 168 53.33 
11-15 Years 48 15.23 
16-20 Years 32 10.15 
21-25 Years 13 4.12 
 
 
Figure 13: Plot of overall study population based on duration of T2DM (n=315) 
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Table 8: Distribution of study population based on prescribing pattern (n=315) 
SN PRESCRIBING PATTERN POPULATION PERCENTAGE (%) 
1.  EMPAGLIFLOZIN + INSULIN 20 6.34 
2. EMPAGLIFLOZIN + BIGUANIDES 27 8.57 
3. 
EMPAGLIFLOZIN + BIGUANIDES + 
INSULIN 
43 13.65 
4. 
EMPAGLIFLOZIN + BIGUANIDES + 
INSULIN + SU 
32 10.15 
5. 
EMPAGLIFLOZIN + BIGUANIDES + 
INSULIN + DPP4 
51 16.19 
6. 
EMPAGLIFLOZIN + BIGUANIDES + DPP4 + 
SU 
50 15.87 
7. 
EMPAGLIFLOZIN + BIGUANIDES + α-
glucosidase inhibitors 
6 1.90 
8. EMPAGLIFLOZIN + BIGUANIDES + DPP4 28 8.88 
9. EMPAGLIFLOZIN + INSULIN + SU 12 3.80 
10. EMPAGLIFLOZIN + BIGUANIDES + SU 46 14.60 
 
Figure 14: Plot of overall study population based on prescribing pattern (n=315) 
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Table 9: Distribution of study population based on duration of T2DM and treatment 
received (n=315) 
 
Figure 15: Plot of overall study population based on duration of T2DM and treatment 
received (n=315) 
 
 
 
TREATMENT EMPAGLIFLOZIN + INSULIN ± OHA EMPAGLIFLOZIN + OHA 
DURATION OF T2DM Population Percentage (%) Population 
Percentage 
(%) 
≤5 Years 11 3.49 43 13.65 
>5 Years 122 38.73 139 44.12 
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Table 10: Effect of SGLT-2 inhibitor on body weight (n=315) 
DURATION 
OF T2DM >5 Years ≤5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
 
Empagliflozin 
+ Insulin ± 
OHA 
79.53±14.32 78.2±13.65 (*0.001) 
77.27±13.58
(*0.000) 81.05±11.21
79.98±10.97 
(*0.000) 
78.97±10.7 
(*0.000) 
 
Empagliflozin 
+ OHA 
86.86±16.09 85.12±14.96(*0.000) 
84.12±14.78
(*0.000) 78.96±11.38
77.81±11.43 
(*0.000) 
76.85±11.32
(*0.000) 
**p value ≤0.001 is considered to be statistically significant 
Figure 16: Plot for effect of SGLT-2 inhibitor on body weight (n=315) 
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Table 11: Effect of SGLT-2 inhibitor on BMI (n=315) 
DURATION 
OF T2DM ≤5 Years >5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
Empagliflozin 
+ Insulin ± 
OHA 
29.7±4.5 29.20±4.24(*0.082) 
28.87±4.18 
(*0.004) 29.60±3.30
29.24±3.24 
(*0.000) 
28.89±3.13 
(*0.000) 
Empagliflozin 
+ OHA 31.53±4.93 
30.93±4.61
(*0.000) 
30.44±4.50 
(*0.000) 28.56±2.54
28.16±2.56 
(*0.000) 
27.93±2.66 
(*0.000) 
**p value ≤0.001 is considered to be statistically significant 
Figure 17: Plot for effect of SGLT-2 inhibitor on BMI (n=315) 
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Table 12: Effect of SGLT-2 inhibitor on FBS (n=315) 
DURATION 
OF T2DM ≤5 Years >5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
Empagliflozin 
+ Insulin ± 
OHA 
246.45±93.30 217.09±110.98 (*0.265) 
180.81±77.97 
(*0.008) 228.39±71.06 
176.61±54.31 
(*0.000) 
140.22±45.44 
(*0.000) 
Empagliflozin 
+ OHA 184.95±41.97 
150.40±34.69 
(*0.000) 
116.65±25.15 
(*0.000) 205.72±57.32 
116.22±46.87 
(*0.000) 
129.53±38.31 
(*0.000) 
**p value ≤0.001 is considered to be statistically significant 
 
Figure 18: Plot for the effect of SGLT-2 inhibitor on FBS (n=315) 
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Table 13: Effect of SGLT-2 inhibitor on RBS (n=315) 
DURATION 
OF T2DM ≤5 Years >5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
Empagliflozin + 
Insulin ± OHA 333±137.48 
245.81±93.97 
(*0.009) 
199.81±71.92 
(*0.001) 288.21±85.64
234.16±55.02 
(*0.000) 
203.69±41.39 
(*0.000) 
Empagliflozin + 
OHA 256.91±53.49 
217.51±40.38 
(*0.000) 
181±33.54 
(*0.000) 272.69±55.61
233.46±44.57 
(*0.000) 
191.07±35.73 
(*0.000) 
**p value ≤0.001 is considered to be statistically significant 
 
Figure 19: Plot for the effect of SGLT-2 inhibitor on RBS (n=315) 
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Table 14: Effect of SGLT-2 inhibitor on HbA1c (n=315) 
DURATION OF 
T2DM ≤5 Years >5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
Empagliflozin + Insulin 
± OHA 11.33±1.67 
9.4±1.21 
(*0.000) 
8.57±1.03 
(*0.000) 9.43±1.32 
8.45±0.92 
(*0.000) 
7.82±0.85 
(*0.000) 
Empagliflozin + OHA 8.30±0.86 7.72±0.76 (*0.000) 
7.19±0.58 
(*0.000) 8.56±1.16 
7.90±0.98 
(*0.000) 
7.47±0.84 
(*0.000) 
**p value ≤0.001 is considered to be statistically significant 
 
Figure 20: Plot for the effect of SGLT-2 inhibitor on HbA1c (n=315) 
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Table 15: Effect of SGLT-2 inhibitor on total cholesterol (n=315) 
DURATION 
OF T2DM ≤5 Years >5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
Empagliflozin 
+ Insulin ± 
OHA 
200.72±58.50 198.27±48.39 (*0.616) 
194.63±44.15 
(*0.302) 225.94±75.09
216.94±65.51 
(*0.008) 
209.84±62.58 
(*0.006) 
Empagliflozin 
+ OHA 221.67±65.37 
207.12±59.09 
(*0.006) 
200.63±54.66 
(*0.005) 241.25±87.77
228.87±79.78 
(*0.006) 
219.50±71.01 
(*0.004) 
**p value ≤0.001 is considered to be statistically significant 
 
Figure 21: Plot for the effect of SGLT-2 inhibitor on total cholesterol (n=315) 
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Table 16: Effect of SGLT-2 inhibitor on triglycerides (n=315) 
DURATION 
OF T2DM ≤5 Years >5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
Empagliflozin + 
Insulin ± OHA 216±60.57 
202.09±56.11 
(*0.008) 
208.09±75.67 
(*0.297) 238.82±78.48
225.89±72.23 
(*0.241) 
219.22±68.43 
(*0.009) 
Empagliflozin + 
OHA 223.56±77.77 
211.74±66.97 
(*0.007) 
199.74±62.72 
(*0.006) 256.06±89.14
242.12±83.47 
(*0.041) 
233.25±79.75 
(*0.006) 
**p value ≤0.001 is considered to be statistically significant 
 
Figure 22: Plot for the effect of SGLT-2 inhibitor on triglycerides (n=315) 
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Table 17: Effect of SGLT-2 inhibitor on HDL level (n=315) 
DURATION 
OF T2DM ≤5 Years >5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
Empagliflozin + 
Insulin ± OHA 37.45±3.14 
37.45±2.84 
(*1.000) 
38.09±3.98 
(*0.111) 34.30±4.25 
34.64±3.96 
(*0.003) 
35.21±3.64 
(*0.000) 
Empagliflozin + 
OHA 35.67±4.42 
35.91±4.30 
(*0.455) 
36.19±4.07 
(*0.053) 34.96±6.59 
35.07±5.99 
(*0.467) 
35.86±5.62 
(*0.000) 
**p value ≤0.001 is considered to be statistically significant 
 
Figure 23: Plot for the effect of SGLT-2 inhibitor on HDL level (n=315) 
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Table 18: Effect of SGLT-2 inhibitor on LDL level (n=315) 
DURATION 
OF T2DM ≤5 Years >5 Years 
TREATMENT Baseline After 2 Months 
After 4 
Months Baseline 
After 2 
Months 
After 4 
Months 
Empagliflozin + 
Insulin ± OHA 98.45±53.19 
96.90±45.49 
(*0.729) 
96.27±46.43 
(*0.646) 116.61±41.74
107.69±38.10 
(*0.000) 
102.52±36.17 
(*0.000) 
Empagliflozin + 
OHA 117.77±49.52 
112.95±44.97 
(*0.092) 
109.12±41.82 
(*0.003) 117.21±52.09
112.17±45.32 
(*0.004) 
107.69±42.17 
(*0.000) 
**p value ≤0.001 is considered to be statistically significant 
 
Figure 24: Plot for the effect of SGLT-2 inhibitor on LDL level (n=315) 
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Table 19: Distribution of ADR in the study population (n=315) 
TREATMENT 
DURATION OF 
T2DM 
 
≤5 Years 
 
>5 Years 
ADR After 2 Months 
After 4 
Months 
After 2 
Months 
After 4 
Months 
 
Empagliflozin + 
Insulin ± OHA 
Hypoglycemia 2 0 26 14 
Geno mycotic 
infection 0 0 0 0 
Ketoacidosis 0 0 0 0 
 
Empagliflozin + 
OHA 
Hypoglycemia 0 1 5 2 
Geno mycotic 
infection 0 0 1 1 
Ketoacidosis 0 0 0 0 
 
Figure 25: Plot for the events of hypoglycemia in the study population (n=315) 
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Table 20: Distribution of ADR based on Naranjo ADR Scale in the study population 
(n=315) 
NARANJO 
SCALE 
≤5 Years >5 Years 
Empagliflozin + 
Insulin ± OHA 
(n=11) 
Empagliflozin + 
OHA 
(n=43) 
Empagliflozin + 
Insulin ± OHA 
(n=122) 
Empagliflozin + 
OHA 
(n=139) 
After 2 
Months 
After 4 
Months 
After 2 
Months
After 4 
Months 
After 2 
Months 
After 4 
Months 
After 2 
Months 
After 4 
Months 
Definite 
ADR 0 0 0 0 0 0 0 0 
Probable 
ADR 0 0 0 0 0 0 1 1 
Possible 
ADR 
2 
(18%) 0 0 0 
26 
(21.31%) 
12 
(9.83%) 
5 
(3.59%)
1 
(0.71%)
Doubtful 
ADR 0 0 0 
1 
(2.32%) 0 
2 
(1.63%) 0 1 
 
Table 21: Distribution of study population based on Morisky Patient Medication 
Adherence Scale (n=315) 
MORISKY 
SCALE 
≤5 Years >5 Years 
Empagliflozin+ 
Insulin ± OHA 
(n=11) 
Empagliflozin + 
OHA 
(n=43) 
Empagliflozin + 
Insulin ± OHA 
(n=122) 
Empagliflozin + 
OHA 
(n=139) 
After 2 
Months 
After 4 
Months 
After 2 
Months
After 4 
Months 
After 2 
Months 
After 4 
Months 
After 2 
Months
After 4 
Months 
Low 
adherence 0 0 0 0 
11 
(9.01%) 0 
1 
(1.7%) 0 
Medium 
adherence 
2 
(18.18%) 0 
3 
(6.9%) 
2 
(4.6%) 
18 
(14.75%)
13 
(10.6%) 
10 
(7.7%) 
4 
(2.8%) 
High 
adherence 
9 
(81%) 
11 
(100%) 
40 
(93%) 
41 
(95.3%)
93 
(76.22%)
109 
(89.3%) 
128 
(92%) 
135 
(97.1%)
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Table 22: Relationship between hypoglycemic episodes and patient medication adherence 
in insulin taking group 
EMPAGLIFLOZIN + INSULIN ± OHA 
ADR Duration of T2DM 
High adherence Medium adherence Low adherence 
After 2 
Months 
After 4 
Months 
After 2 
Months 
After 4 
Months 
After 2 
Months 
After 4 
Months 
Hypoglycemia 
≤5 Years 0 0 3 0 0 0 
>5 Years 5 (4.06%) 
1 
(0.81%) 
10 
(8.19%) 
13 
(10.65%) 
11 
(9.01%) 
0 
(0%) 
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Table 23: Student paired t-test for empagliflozin + insulin ± OHA therapy 
**p value ≤0.001 is considered to be statistically significant 
Parameter Duration of T2DM 
Baseline R-1 R-2 
R-1 
t-value 
R-2 
t-value 
R-1 
p-
value 
R-2 
p-
value Mean ± SD Mean ± SD Mean ± SD 
EMPAGLIFLOZIN + INSULIN ± OHA 
BODY 
WEIGHT 
≤5 Years 79.55±14.320 78.18±13.65 77.27±13.58 4.892 5.926 0.000 0.000 
>5 Years 81.05±11.21 79.98±10.97 78.97±10.7 12.727 15.534 0.001 0.000 
BMI 
≤5 Years 29.64±4.5 29.36±4.2 28.91±4.1 1.936 3.730 0.082 0.004 
>5 Years 29.60±3.3 29.24±3.24 28.89±3.13 7.096 10.920 0.000 0.000 
FBS 
≤5 Years 246.45±93.30 217.09±110.98 180.82±77.97 1.180 3.313 0.265 0.008 
>5 Years 228.39±71.06 176.61±54.31 140.22±45.44 13.460 18.871 0.000 0.000 
RBS 
≤5 Years 333±137.48 245.82±93.97 199.82±71.92 3.222 4.589 0.009 0.001 
>5 Years 288.21±85.64 234.16±55.02 203.69±41.39 11.798 14.387 0.000 0.000 
HbA1c 
≤5 Years 11.27±1.67 9.45±1.21 8.55±1.03 6.901 7.596 0.000 0.000 
>5 Years 9.43±1.32 8.45±0.92 7.82±0.85 12.038 20.015 0.000 0.000 
Total 
cholesterol 
≤5 Years 200.73±58.50 198.27±48.39 194.64±44.150 0.518 1.087 0.616 0.302 
>5 Years 225.94±75.09 216.94±65.51 209.84±62.58 5.810 8.197 0.008 0.006 
Triglyceride 
≤5 Years 216±60.57 202.09±56.11 208.09±75.67 3.330 1.099 0.616 0.302 
>5 Years 238.82±78.48 225.89±72.23 219.22±68.43 7.852 9.212 0.241 0.009 
HDL 
≤5 Years 37.45±3.14 37.45±2.84 38.09±3.98 0.000 1.750 1.000 0.111 
>5 Years 34.3±4.25 34.64±3.96 35.21±3.64 3.067 6.964 0.003 0.000 
LDL 
≤5 Years 98.45±53.19 96.91±45.49 96.27±46.43 0.356 0.474 0.729 0.646 
>5 Years 116.61±41.74 107.69±38.10 102.36±36.17 5.195 6.891 0.000 0.000 
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Table 24: Student paired t-test for empagliflozin + OHA therapy 
**p value ≤0.001 is considered to be statistically significant 
Parameter Duration of T2DM 
Baseline R-1 R-2 
R-1 
t-value 
R-2 
t-value 
R-1 
p-
value 
R-2 
p-
value Mean ± SD Mean ± SD Mean ± SD 
EMPAGLIFLOZIN + OHA 
BODY 
WEIGHT 
≤5 Years 86.86±16.09 85.12±14.96 84.12±14.78 5.616 6.967 0.000 0.000 
>5 Years 78.96±11.21 77.81±11.43 76.85±11.32 9.739 16.454 0.000 0.000 
BMI 
≤5 Years 31.53±4.93 30.93±4.61 30.44±4.50 5.013 7.572 0.000 0.000 
>5 Years 28.56±2.54 28.16±2.56 27.93±2.66 7.057 6.854 0.000 0.000 
FBS 
≤5 Years 184.95±41.97 150.40±34.69 116.65±25.15 8.061 10.490 0.000 0.000 
>5 Years 205.72±57.32 116.22±46.87 129.53±38.31 11.704 19.284 0.000 0.000 
RBS 
≤5 Years 256.91±53.49 217.51±40.38 181±33.54 5.897 10.225 0.000 0.000 
>5 Years 272.69±55.61 233.46±44.57 191.07±35.73 12.462 22.123 0.000 0.000 
HbA1c 
≤5 Years 8.3±0.86 7.72±0.76 7.19±0.58 6.998 11.707 0.000 0.000 
>5 Years 8.56±1.16 7.9±0.98 7.47±0.98 10.251 16.478 0.000 0.000 
Total 
cholesterol 
≤5 Years 221.67±65.37 207.12±59.09 200.63±54.66 4.268 5.268 0.006 0.005 
>5 Years 241.25±87.77 228.87±79.78 219.5±79.78 5.624 9.526 0.006 0.004 
Triglyceride 
≤5 Years 223.56±77.77 211.74±66.97 199.74±62.72 3.837 5.661 0.007 0.006 
>5 Years 256.06±89.14 242.12±83.47 233.25±79.75 8.655 13.028 0.041 0.006 
HDL 
≤5 Years 35.67±4.42 35.91±4.30 36.19±4.07 0.754 1.995 0.455 0.053 
>5 Years 34.96±6.59 35.07±5.99 35.85±5.62 0.730 6.088 0.467 0.000 
LDL 
≤5 Years 117.77±49.52 112.95±44.97 109.12±41.82 1.725 3.175 0.092 0.003 
>5 Years 117.21±52.09 112.17±45.32 107.69±42.17 2.939 6.136 0.004 0.000 
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6. RESULTS 
 A total of 315 patients receiving SGLT-2 inhibitor as a therapy for T2DM were enrolled in 
the study. These patients received 10 different combinations of SGLT-2 inhibitors based on the 
pharmacological classification (Table 8 and Figure 14). The results show that, empagliflozin was 
the most prescribed SGLT-2 inhibitorwhile canagliflozin and dapagliflozin were the least. The 
most prescribed combination with empagliflozin was biguanides or insulin along with other 
combinations such as DPP4, sulfonylurea and α-glucosidase inhibitors. Mostly prescribed 
combination was empagliflozin + biguanides + insulin + DPP4 (16.19%) followed by 
empagliflozin + biguanide + DPP4 + SU (15.87%). Empagliflozin + biguanides + SU (14.6%), 
empagliflozin + biguanide + insulin (13.65%), empagliflozin + biguanide + insulin + SU 
(10.15%), empagliflozin + biguanides + DPP4 (8.88%), empagliflozin + biguanides (8.57%), 
empagliflozin + insulin (6.34%) were the major other prescribing pattern whereas empagliflozin 
+ insulin + SU (3.8%) and empagliflozin + α-glucosidase inhibitors (1.9%) are the least 
prescribed pattern. 
GENERAL DEMOGRAPHIC CHARACTERISTICS OF THE STUDY POPULATION: 
 The patients were categorized based on their gender. There were 188 males (59.7%) and 127 
females (40.3%) in the study. The result of this study shows higher predominance of male for 
T2DM. (Table 3 and Figure 9). 
 Study population was categorized into 7 groups based on the age. It was found that about 
38.41% patients were under the age category of 51-60and least were in the age category of 81-90 
years. (Table 4 and Figure 10). 
  Results 
 
Department of Pharmacy Practice 55 
 
 About 42.85% of the study population had previous medical history of hypertension and 15% 
of the patients had established CV disease(Table 5 and Figure 11). 
 SGLT-2 inhibitors are mostly prescribed to over-weight (63.49%) and obese (32.06%) 
patients(Table 6 and Figure 12). In the study population 17.14% patients had less than 5 years of 
established T2DM whereas 82.85% patients had more than 5 years of T2DM (Table 7 and Figure 
13). 
 So,the study population were divided into two groups namely patients with ≤5 years of 
T2DM and >5 years of T2DM. They are further divided into two sub-groups namely 
empagliflozin with insulin ± OHA and empagliflozin with OHA. (Table 7 and Figure 7) 
 All the T2DM patients enrolled in the study was reviewed at 2 months and 4 months. The 
primary composite outcomes were change in HbA1c, FBS, RBS from baseline as glycemic 
control and change in body weight, BMI, lipid profile and eGFR as beneficial effect of the drug.  
GLYCEMIC CONTROL: 
 The glycemic efficacy was assessed by analyzing the mean change in the value of Fasting 
Blood Sugar (FBS), Random Blood Sugar (RBS) and Glycated hemoglobin (HbA1c) from the 
baseline to 2 months followed by 4 months. 
OTHER PARAMETERS: 
 Change in body weight and lipid profile was also assessed by analyzing the mean value of 
body weight, BMI, total cholesterol, triglycerides, HDL and LDL. 
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CLINICAL EFFICACY OF SGLT-2 INHIBITOR: 
 Based on the study, it was found that, glucose lowering effect were more in patients treated 
with empagliflozin + insulin ± OHA with marked decrease in HbA1c whereas FBS were more 
reduced in patients with longer duration of T2DM while RBS shows a significant reduction in 
patients treated with insulin. 
 The study demonstrates, more reduction in the HbA1c among the patients treated with 
empagliflozin + insulin ± OHAwith a mean reduction of 1.93% (9.4±1.21 with p value ≤0.001) 
and 2.76% (8.57±1.03 with p value ≤0.001) after 2 months and 4 months respectively among the 
patients with≤5 years of T2DM. Empagliflozin + insulin ± OHA shows similar reduction of 
HbA1c in >5 years group by 0.98% (8.45±0.92 with p value ≤0.001) and 1.61% (7.82±0.85 with 
p value ≤0.001) after 2 months and 4 months of therapy respectively. Empagliflozin + OHA 
treated group also showed a significant reduction in the HbA1c by 0.58% (7.72±0.76 with p 
value ≤0.001) and 1.11% (7.19±0.58 with p value ≤0.001) in ≤5 years and 0.66% (7.90±0.98 
with p value ≤0.001) and 1.09% (7.47±0.84 with p value ≤0.001) in >5 years after 2 months and 
4 months respectively (Table 14 and Figure 20). 
 More the duration of T2DM more was the decrease in FBS. Empagliflozin + OHA in ≥5 
years of T2DM shows a significant mean reduction in the FBS by 89.53mg/dl (116.22±46.87 
with p value ≤0.001) and 91.22 mg/dl (129.53±38.31 with p value ≤0.001) after 2 months and 4 
months respectively. Empagliflozin + insulin ± OHA also shows almost similar significant 
reduction in the FBS by 51.78mg/dl (176.61±54.31 with p value ≤0.001) and 88.17mg/dl 
(140.22±45.44 with p value ≤0.001) after 2 and 4 months respectively. FBS lowering effect 
withempagliflozin + insulin ± OHA and empagliflozin + OHA were almost similar with mean 
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reduction by 29.36mg/dl (217.09±110.98 with p value ≤0.265) and 34.55mg/dl (150.40±34.69 
with p value ≤0.001) after 2 months respectively and 65.64mg/dl (180.81±77.97 with p value 
≤0.008) and 68.3mg/dl (116.65±25.15 with p value ≤0.001) after 4 months respectively (Table 
12 and Figure 18). 
 The study shows significant reduction in the RBS in all groups. The mean reduction of RBS 
was more in empagliflozin + insulin ± OHA treated group with mean reduction of 87.19mg/dl 
(245.81±93.97 with p value ≤0.009) and 54.05mg/dl (234.16±55.02 with p value ≤0.001) after 2 
months in ≤5 years and >5 years of T2DM respectively. The mean reduction was 133.19mg/dl 
(199.81±71.92 with p value ≤0.001) and 54.05mg/dl (234.16±55.02 with p value ≤0.001) after 4 
months in ≤5years and >5 years respectively. Empagliflozin + OHA also shows a significant 
reduction in the both ≤5 years and >5 years group. After 2 months of therapy, the mean reduction 
of 39.4mg/dl (217.51±40.38 with p value ≤0.001) and 39.23mg/dl (233.46±44.57 with p value 
≤0.001) in ≤5 years and >5 years group respectively. After 4 months of therapy, the mean 
reduction was 75.91mg/dl (181±33.54 with p value ≤0.001) and 81.62mg/dl (191.07±35.73 with 
p value ≤0.001) in ≤5 years and >5 years respectively (Table 13 and Figure 19). 
 Change in body weight were more in patients with ≤5 years of T2DM. There was a mean 
reduction of 1.74kg (85.12±14.96 with p value ≤0.001) and 2.74kg (84.12±14.78 with p value 
≤0.001) in empagliflozin + OHA with ≤5 years of T2DM after 2 months and 4 months 
respectively. Also, there was mean reduction of 1.33 kg (78.2±13.65 with p value ≤0.001) and 
2.26kg (77.27±13.58 with p value ≤0.001) after 2 and 4 months respectively in empagliflozin + 
insulin ± OHA group. Therapy with empagliflozin +OHA in >5 years of T2DM shows a 
significant mean reduction by 1.15kg (77.81±11.43 with p value ≤0.001) and 2.11kg 
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(76.85±11.32 with p value ≤0.001) after 2 and 4 months respectively. About 1.07 kg 
(79.98±10.97 with p value 0.001) and 2.08kg (78.97±10.7 with p value ≤0.001) mean reduction 
of body weight was recorded after 2 months and 4 months respectively in empagliflozin + insulin 
± OHA treated patients with >5 years of T2DM (Table 10 and Figure 16). 
 BMI lowering effect was more in ≤5 years of T2DM patients. Empagliflozin + OHA treated 
patients with ≤5 years of T2DM was reported mean reduction of 0.6kg/m2 (30.93±4.61 with p 
value ≤0.001) and 1.09kg/m2 (30.44±4.50 with p value ≤0.001) after 2 months and 4 months 
respectively. Empagliflozin + insulin ± OHA treated patients also reported significant reduction 
in BMI by 0.5kg/m2 (29.20±4.24 with p value ≤0.001) and 0.36kg/m2 (29.24±3.24 with p value 
≤0.001) after 2 months for ≤5 years and >5 years of T2DM. Mean reduction of BMI in >5 years 
of T2DM treated with empagliflozin + OHA found to be least but it also shows a significant 
change in 2 months and 4 months by 0.41kg/m2 (28.16±2.56 with p value ≤0.001) and 0.63kg/m2 
(27.93±2.66 with p value ≤0.001) respectively (Table 11 and Figure 17). 
 The study demonstrates that, the lipid profile was well maintained in all groups (which 
includes patients with or without statins). The mean total cholesterol for empagliflozin + insulin 
± OHA in ≤5 years was 198.27±48.39 and 194.63±44.15 after 2 months and 4 months 
respectively, while for >5 years it was 216±65.65 and 209±62.58 after 2 months and 4 months 
respectively. There was a similar effect on empagliflozin + OHA treated group with mean total 
cholesterol of 207.12±59.09 and 200.63±54.66 after 2 months and 4 months respectively in ≤5 
years group while in >5 years mean total cholesterol was 228.87±79.78 and 219.50±71.01 after 2 
months and 4 months of therapy respectively (Table 15 Figure 21). 
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 The level of triglycerides was well maintained after the 4-month duration of therapy with or 
without statin in all the groups. It reflects its beneficial effect towards the patients with 
hyperlipidemia with T2DM. The mean triglycerides level in empagliflozin + insulin ± OHA 
treated group was 202.09±56.11 and 208.09±75.67 after 2 and 4 months respectively in <5 years 
of T2DM while it was 225.89±72.23 and 219.22±68.43 in >5 years after 2 and 4 months 
respectively. The result was similar in empagliflozin + OHA treated group with mean 
triglycerides level of 211.74±66.97 and 199.74±62.72 in 2 and 4 months respectively in ≤5 years 
of T2DM, but it was 242.12±83.47 and 233.25±79.75 in >5 years respectively (Table 16 and 
Figure 22). 
 The HDL level was found slightly increased in the study population with or with statin. 
Empagliflozin + insulin ± OHA in ≤5 years shows mean HDL of 37.45±2.84 and 38.09±3.98 
after 2 and 4 months respectively but in >5 years it was 34.64±3.96 and 35.21±3.64 after 2 and 4 
months of therapy. While in empagliflozin + OHA treated group mean HDL level was 
35.91±4.30 and 36.19±4.07 after 2 and 4 months respectively in ≤5 years while, 35.07±5.99 and 
35.86±5.62 after 2 and 4 months respectively in ≥5 years of T2DM patients (Table 17 and Figure 
23) 
 The LDL level after the therapy doesn’t show much reduction but well maintained. 
Empagliflozin + insulin ± OHA in ≤5 years of T2DM shows mean LDL level of 96.90±45.49 
and 96.27±46.43 after 2 and 4 months respectively. But, in >5 years of T2DM it was 
107.69±38.10 and 102.52±36.17 after 2 and 4 months respectively. In empagliflozin + OHA 
treated group, LDL level was 112.95±44.97 and 109.12±41.82 in ≤5 years of T2DM after 2 and 
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4 months respectively while it was 112.17±45.32 and 107.69±42.17 in ≥5 years of T2DM (Table 
18 and Figure 24). 
 The eGFR level was ≥60ml/min/1.73m2 in all the groups after the 4 months therapy. The 
eGFR level ≥40ml/mon/1.73m2 was considered as an inclusion criterion, as explained in the 
methodology. 
SAFETY OF SGLT-2 INHIBITORS: 
 After 2 months of therapy, hypoglycemia was the major ADR reported and out of which 26 
(21%) + 2 (18%) reported hypoglycemia was in empagliflozin + insulin ± OHA treated group in 
>5 years and ≤5 years respectively. Empagliflozin + OHA in ≤5 years doesn’t report any 
hypoglycemic events after 2 months but >5 years of T2DM reported 5 (3.5%) cases of 
hypoglycemia (Table 19 and Figure 25). 
 But the catching point is that, there were only 14 cases (11.47%) of hypoglycemia were 
reported in the empagliflozin + insulin ± OHA treated patients after 4 months of therapy. Also, 
only 2 (1.43%) and 1case(2.3%) of hypoglycemia were reported in empagliflozin + OHA treated 
patients in >5 years and ≤5 years of T2DM respectively. 
 There were only 1 case of geno-mycotic infection reported in the entire study population, 
particularly in empagliflozin + OHA treated patients for >5 years of T2DM (Table 19). 
 No events of diabetic ketoacidosis were reported in the entire study population. 
 All the reported ADR was confirmed by Naranjo Adverse Drug Reaction Scale and which 
shows, 21.1% , 18%, and 3.59% of theADR which was reported in empagliflozin + insulin ± 
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OHA in ≥5 years, empagliflozin + insulin ± OHA in ≤5 years and empagliflozin + OHA in >5 
years respectively was confirmed as possible ADR after 2 months of therapy while only 9.83% 
and 0.71% of reported ADR in empagliflozin + insulin ± OHA in >5 years and empagliflozin + 
OHA in >5 years of T2DM respectively was confirmed as possible ADR followed by 2.32% and 
1.63% of doubtful ADR was reported in empagliflozin + OHA in ≤5 years and empagliflozin + 
insulin ± OHA in >5 years of T2DM respectively after 4 months of therapy (Table 20). 
 After 2 months of therapy, the study population were divided into three based on their 
adherence towards the medication using Morisky Patient Medication Adherence Scale. The 
result shows, insulin taking group had lower adherence towards the medication. But, after the 
counselling given to from diabetic clinic (DMTAC), the adherence was improved which was 
recorded after 4 months (Table 21 and 22). 
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7. DISCUSSION 
 The study was designed to identify the prescribing pattern of SGLT-2 inhibitors. The study 
reveals 10 different prescribing patterns for empagliflozin, 2 for canagliflozin and no 
dapagliflozin receiving patients were found in this 6-month study. Patients receiving 
canagliflozin were excluded for the clinical efficacy study because of the limited number of 
cases. Among the 10 prescribing patterns of empagliflozin, about 16.19% of the study population 
received empagliflozin + biguanides + insulin + DPP4. There is no previous study conducted on 
these combinations except thatRosenstock et al., (2014)77 conducted a study on improved 
glycemic control with empagliflozin + biguanide + insulin. Also, Scheenet al., (2016)79 
performed a combination therapy with DPP-4 inhibitors. Both the studies showed a significant 
reduction in the glycemic control and body weight which was quite similar to the present study. 
Empagliflozin was mostly prescribed as second-line therapy after metformin. According to 
Defronzoet al., (2015)66 empagliflozin + gliptin combination was effective on patients with 
inadequately controlled T2DM with metformin. In our study, 40.95% of the study population 
received empagliflozin + gliptins ± insulin or other OHAs. 
 Empagliflozin + insulin ± OAH was received by 50.15% of the study population. According 
to Rosenstock et al., (2015)70 empagliflozin as an addon to insulin in patients with inadequately 
controlled T2DM was effective in improving glycemic control and reduced body weight with 
similar risk of hypoglycemia as that of placebo. 
 About 44.4% of the study population received different combinations with sulfonylureas. 
According to Haeringet al., (2015)73 empagliflozin as add-on to metformin and sulfonylureas 
shows a significant reduction in the HbA1c and weight versus placebo. 
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 Empagliflozin + biguanides with α-glucosidase inhibitor was the least prescribed 
combination in our study. 
 In the present study, we enrolled 315 patients receiving empagliflozin as a therapy for 
T2DM. The study was categorized based on gender. There were 188 (59.7%) of male and 127 
(40.3%) of female in the entire study population. This result shows higher predominance for 
T2DM in male than in female.This was similar to the previous study conducted by Gale et al., 
(2011)80 which showed higher prevalence of T2DM in men than women. 
 The study population were then categorized based on the age group, where 38.4% of the 
study population came under the age group of 51-60 years. This was similar to the study 
conducted byBasimet al., (2017)81 where the mean age was 56.4 years.          
 Among the study population, hypertension was the major comorbidity reported (42.9%), 
followed by myocardial infraction (8.3%), stroke (0.6%) and angina (6%). The result was similar 
to the previous study conducted by Lastraet al., (2014)82 which showed hypertension is present 
in 50% of patients with T2DM and contribute significantly to macrovascular and microvascular 
complications in diabetes mellitus. 
 According to Muhammadet al., (2016)83 myocardial infraction, stroke and angina are the 
major comorbidities associated with T2DM. 
 Among the study population, a greater number of patients were over-weight (63.49%) and 
Obese (32.06%). This revels, over-weight and obese patients are more prone to get T2DM. 
According toTorgerson et al., (2004)84 risk of affecting T2DM is mostly linked to presence and 
duration of over-weight and obesity. 
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 The study population was categorized into five groups based on the duration of T2DM. 
About 53.3% of the study population had 6-10 years of T2DM. Astudy conducted by Cortez et 
al., (2014)85 which showed 28.2% had diabetes for <5 years, 35.2% had 5-10 years of diabetes 
while 36.6% of the study population had >10 years of diabetes. 
 The study population was then divided into two based on the therapy received, namely 
empagliflozin + insulin ± OHA and empagliflozin ± OHA. Which was further subdivided into 
two, namely patients with ≤5 years and >5 years of T2DM. 
 Among the sub-divided group, a greater number of patients had more than 5 years of T2DM 
i.e., 44.12% in empagliflozin + OHA and 38.73% in empagliflozin + insulin ± OHA treated 
group. 
 The glucose lowering efficacy was assessed by analyzing the mean change in the value of 
HbA1c, Fasting blood sugar (FBS), and Random blood sugar (RBS) from the start of the therapy 
to the end of 4 months study period in each group with follow-up at the end of 2nd month. The 
beneficial effect of empagliflozin such as body weight, BMI, total cholesterol, triglycerides, 
HDL and LDL was assessed at 2 months followed by 4 months. 
 Empagliflozin has been demonstrated to improve glycemic control when used in combination 
with insulin or with other OHAs. In this study, the reduction in HbA1c with empagliflozin + 
insulin was greater than those with empagliflozin + OHA treated group. 
 In this study, at the end of 4 months of therapy HbA1c, FBS and RBS were significantly (p 
value ≤0.001) reduced by 8.57±1.03, 180.81±77.97 and 199.81±71.92 respectively in ≤5 years 
and 7.82±0.85, 140.22±45.44 and 203.69±41.39 in >5 years of T2DM in empagliflozin + insulin 
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± OHA treated patients. The result of this study perfectly complies with the former study 
conducted by Rosenstock et al., (2014)77were the empagliflozin add-on to insulin improved 
glycemic control and body weight with similar risk of hypoglycemia to placebo. 
 Another study conducted by Rosenstock et al., (2015)70 there was statistically significant 
improvement in the HbA1c with empagliflozin + insulin treated group. Addition of 
empagliflozin to insulin improved glycemic control, lower insulin doses and achieved HbA1c 
level of 7.2% and 7.1% in 10 mg and 25 mg respectively. In the clinical trial conducted in 
various sites, it has been shown to be safe and effective in T2DM patients when used as an add-
on to insulin ± other OHA. 
 In the study population empagliflozin + OHA treated patients also shows a significant (p 
value ≤0.001) reduction in the HbA1c, FBS and RBS, but, the reduction was more in insulin 
treated group.A study conducted by Araki et al., (2015)72 also shows Japanese T2DM patients 
treated with empagliflozin as an add-on to other oral anti-diabetic therapy for 52 weeks were 
well tolerated and were associated with clinically meaningful reduction in the HbA1c. 
 Astudy conducted by Goldman et al., (2018)86 concludes, combination therapy with 
empagliflozin and metformin in T2DM who were inadequately controlled by metformin was 
effective in glucose lowering. 
 Another study conducted by Kawamoriet al., (2018)54 where the combination therapy with 
empagliflozin and linagliptin shows significant reduction in the HbA1c in Japanese T2DM 
patients. This was the phase III trial for fixed dose combination of empagliflozin and linagliptin. 
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 Another study conducted by Haeringet al., (2015)73 shows empagliflozin as an add-on to 
metformin and sulfonylurea for 76 weeks was well tolerated and led to sustained reduction of 
HbA1c and weight. 
 In the study population, as the duration T2DM increases, the FBS reduction was also 
increased with empagliflozin treated group. 
 Body weight gaining is one of the serious issues associated with the management of T2DM, 
specially in over-weight or obese patients. In this study, body weight shows a marked decrease in 
all the empagliflozin treated group with minimum mean reduction of 2.08kg in all group after 4 
months of study. Empagliflozin + OHA and empagliflozin + insulin ± OHA shows an almost 
close reduction in the body i.e., 2.74kg and 2.26kg respectively. So, it is a beneficial factor 
which should be considered in the management of T2DM. Also, as we described above, we had 
about 95.52% of study population received empagliflozin was over-weight or obese patients with 
T2DM. So, according to our study, empagliflozin must be a good choice for the management of 
T2DM in over-weight and obese. 
 According to Haeringet al., (2015)73 empagliflozin as an add-on to other OHAs shows a 
significant reduction in the body weight. It was a double-blind trail which included 666 patients 
with T2DM to receive 10mg, 25mg or placebo once daily. 
 Another study conducted by Goldman et al., (2018)86 combination therapy with 
empagliflozin and metformin is very suitable for the patients with T2DM who are inadequately 
controlled with metformin, in particular, patients with modest reduction in the body weight and 
blood pressure. 
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 According to Rosenstock et al., empagliflozin with insulin show significant reduction in 
body weight by 2.2±0.5kg and 2.2±0.5kg in 10mg and 25mg empagliflozin respectively as an 
add-on to insulin. This result compiles with the body weight reduction in insulin treated group in 
our study. 
 Zinmanet al., (2015)69 in EMPA-REG OUTCOME trial shows, empagliflozin was 
associated with reduction in the body weight, waist circumference, uric acid level, systolic and 
diastolic blood pressure with increase in heart rate and good action on HDL and LDL. 
 In this study, BMI was considered as an important parameter because, most of the patients 
were obese and overweight with T2DM and some with other cardiovascular disease. In this 
study, BMI was found a decrease of about 1.09kg/m2 in the empagliflozin + OHA treated group. 
But the result was almost similar with insulin treated group which was 0.83kg/m2 after 4 months 
of therapy in patients. 
 In this study, duration of study was associated with reduction in the BMI. Empagliflozin + 
insulin ± OHA shows a marked decrease in BMI by 0.71kg/m2and 0.63kg/m2 in empagliflozin + 
OHA treated patients after 4 months of therapy. 
 According to Neelandet al., (2016)87 empagliflozin was associated with the higher urinary 
excretion of glucose by reducing the renal tubular threshold for glycosuria. This leads to 
excretion of 60-100g/day of glucose, which results in improving glucose control with lower risk 
of hypoglycemia and results in loss of 240 to 400kCal/day into urine with associated body 
weight and BMI reduction. 
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 Neelandet al., (2016)87studied beneficial effect of empagliflozin on blood pressure. The 
study shows decrease in blood pressure was due to osmotic diuresis of glucose and natriuresis of 
co-transported sodium. 
 In our study, lipid profiles were well maintained in all the empagliflozin received 
group.About 55.5% patients in the entire study population received empagliflozin + statins and 
there were less events of complications reported. All the lipid parameters such as total 
cholesterol, triglycerides, HDL and LDL level were improved with the therapy. 
 But according to the resultscripted byZinmanet al., (2015)69 in EMPA-REG OUTCOME 
trial which included 7020 T2DM patients with established CVD, the empagliflozin was 
associated with slight increase in both HDL and LDL. This might be because in our study 
patients with hyperlipidemia received statins along with empagliflozin. 
 There was not much change found in eGFR level in our study, 99.3% had 
>90ml/min/1.73m2. 
 The treatment with empagliflozin was well tolerated over the 4 months treatment period. 
Mild hypoglycemia (10.47%) and geno-mycotic infection (0.31%) was the adverse events 
reported in the entire study population. These adverse events were confirmed by Naranjo ADR 
Scale. No events of diabetic ketoacidosis were reported among the study population. 
 Geno-mycotic infection was reported in empagliflozin + OHA treated patients, particularly 
with empagliflozin + metformin + glimepiride and the drug were discontinued after 4 months of 
therapy and was treated with topical anti-fungal agents. The result was similar to the study 
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conducted by Zinmanet al., (2015)69 where the events of geno-mycotic infection reported were 
1.7% of the entire study population (n=7020). 
 Hypoglycemic events were more in empagliflozin + insulin ± OHA receiving patients i.e., 
8.8% of entire study population (n=315). The hypoglycemic events were reported more in 
patients with more than 5 years of T2DM i.e., 21% (n=122) and 18 % (n=11) in less than five 
years of T2DM. 
 Particularly, after 2 months of therapy the events of hypoglycemia were more in patients 
received only empagliflozin as an add-on to insulin i.e., 40% (n=20) and 27.9% (n=43) with 
empagliflozin add-on to metformin + insulin. But, after 4 months of therapy the hypoglycemic 
events were lesser in insulin treated patients i.e., 25% and 11.62% in empagliflozin + insulin and 
empagliflozin + metformin + insulin respectively. 
 The result was similar to the study conducted by Rosenstock et al., (2015)70 where the 
reported events of hypoglycemia after 18 weeks of therapy with empagliflozin as an add-on to 
insulin showed 20% and 28%with 10mg and 25mg empagliflozin respectively. But at the end of 
their study i.e., after 72 weeks, there were 36% of reported hypoglycemia in both the doses 
which was similar to placebo. 
 After 2 months of study, the adherence of the patient towards the medication were recorded 
using morisky patient medication adherence scale, which shows insulin receiving patients who 
are reported with hypoglycemia had low (9.01%) or medium adherence (8.19%). So, the patients 
are counselled at diabetic clinic (DMTAC) and reports of hypoglycemia recorded after 4 months, 
which shows, 13% of reported hypoglycemic patients were in medium adherence and only 1% in 
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high adherence. This clearly indicates the relation between patient medication adherence and 
hypoglycemia in insulin receiving patients. 
 During the study period, a cost analysis was conducted among the patients received 
empagliflozin. From the cost analysis study, it was observed that empagliflozin added to 
standard therapy was found cost-effective as the clinical events associated with it is lesser. The 
fact is supported by, Gourzoulidiset al., (2018)88 his study shows empagliflozin added to 
standard of care was estimated to be cost effective. 
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8. CONCLUSION 
 Out of the collected data from 315 patients receiving SGLT-2 inhibitors 12 
prescribing pattern was studied out of which empagliflozin + biguanide + insulin + DPP-4 
was the most prescribed combination followed by empagliflozin +biguanide + DPP-4 + 
SU. There were very few patients who received canagliflozin and no patients with 
dapagliflozin. From the study population, the predominance of T2DM is higher in males 
than females with the age group 51-60 and most of the patients were observed in the 
duration was 6-10 years. The study shows empagliflozin was mostly prescribed to over-
weight or obese patients with/without established cardiovascular complications. 
 The study provides an evidence of safety and efficacy of empagliflozin as add-on 
to insulin or in combination with other OHA in patients with T2DM. 
 The results pointed out that, all the group of patients showed an improvement in 
their glycaemic parameters such as HbA1c, FBS and RBS during the study period and 
from the group comparison study it was observed that patients receiving empagliflozin 
with insulin ± OAH had better glycaemic control than empagliflozin + OHA therapy. 
 The study demonstrates a significant reduction in the body weight and BMI in all 
the groups, but slightly more in patients with ≤5 years of T2DM. It had a beneficial effect 
on HDL and LDL as well. 
 Hypoglycaemia was the most reported ADR among those prescribed with 
empagliflozin + insulin ± OHA only. One patient reported with geno-mycotic infection 
leading to stop of the therapy among empagliflozin + OHA receiving group. 
Conclusion 
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 In conclusion, empagliflozin was found tosignificantly improve glycaemic 
parameters along with reduction in body weight, BMI, HDL and LDL in Indian T2DM 
patients with mild ADR when prescribed as add-on to insulin or other OHA. 
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      DATA COLLECTION FORM 
 
Reg. No.:        OP No.: 
Name:      Age:   Sex: M/F 
Marital status:  Married   Single    
Smoking:  Yes  No    Height: 
Alcohol:  Yes  No 
Family history 
Diabetes mellitus:                 Yes                  No 
Hypertension:                       Yes                  No 
Chronic Kidney Disease:     Yes                  No 
 
Date of initiation of SGLT-2 inhibitor therapy: 
Past medical history Yes No Duration After receiving SGLT-2 inhibitor 
Ist Review IInd Review 
Yes No Yes No 
Diabetes mellitus:        
Hypertension:        
Myocardial infraction:        
Stroke:        
Angina:        
  
Parameters considering 
in the study 
Initial After Ist review After IInd review 
Body weight    
BMI    
Blood pressure 
1. Systolic 
2. Diastolic 
   
FBS    
RBS    
HbA1C    
Total cholesterol    
Triglycerides    
HDL    
LDL    
Creatinine    
eGFR    
Albumin    
TREATMENT 
Initial Ist Review IInd Review 
   
   
   
   
   
   
   
   
   
   
 
ADVERSE DRUG REACTION 
 
Hypoglycaemic episodes 
Ist Review IInd Review 
Yes No Yes No 
    
Genital mycotic infections     
Ketoacidosis     
 
NARANJO ADVERSE DRUG REACTION PROBABILITY SCALE 
QUESTIONS YES NO DO NOT 
KNOW 
SCORE 
(R-1) 
SCORE 
(R-2) 
1. Are there previous conclusive reports on this 
reaction? 
+1 0 0   
2. Did the adverse event appear after the suspected drug 
was administered? 
+2 -1 0   
3. Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was 
administered? 
+1 0 0   
4. Did the adverse event reappear when the drug was re-
administered? 
+2 -1 0   
5. Are there alternative causes (other than drug) that 
could on their own have caused the reaction? 
+1 +2 0   
6. Was the drug detected in blood (or other fluids) in 
concentration known to be toxic? 
+1 0 0   
7. Was the reaction more severe when the dose was 
increased or less severe when the dose was decreased? 
+1 0 0   
8. Did the patient have similar reaction to the same or 
similar drugs in any previous exposure? 
+1 0 0   
9. Was the adverse event confirmed by any objective 
evidence? 
+1 0 0   
10. Did the reaction reappear when a placebo was given?  -1 +1 0   
TOTAL   
SCORING FOR NARANJO ADR MONITORING SCALE: 
➢ 9 = definite ADR 
➢ 5-8 = probable ADR 
➢ 1-4 = possible ADR 
➢ 0 = doubtful ADR 
 
 
MORISKY MEDICATION ADHERENCE SCALE 
 
QUESTIONS PATIENT 
ANSWER 
(Y/N) 
SCORE 
(R-1) 
SCORE 
(R-2) 
1. Do you sometimes forget to take your medicine?    
2. People sometimes miss taking their medicines for 
reasons other than forgetting. Thinking over the past 2 
weeks, were there any days when you did not take your 
medicine? 
   
3. Have you ever cut back or stopped taking your medicine 
without telling your doctor because you felt worse when 
you took it? 
   
4. When you travel or leave home, do you sometimes 
forget to bring along your medicine? 
   
5. Did you take all your medicines yesterday?    
6. When you feel like your symptoms are under control, do 
you sometimes stop taking your medicine? 
   
7. Taking medicine every day is a real inconvenience for 
some people. Do you ever feel hassled about sticking to 
your treatment plan? 
   
8. How often do you have difficulty remembering to take 
all your medicine?  
__ A. Never/rarely 
__ B. Once in a while 
__ C. Sometimes 
__ D. Usually 
__ E. All the time 
• A=0, B-E= 1 
   
*Y=1, N=0 
 
Scores: >2 = low adherence 
1 or 2 = medium adherence 
0 = high adherence 
